Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHARP-SCLC: Standard vs. Hypofractionated Accelerated Radiotherapy in Limited-Stage Small Cell Lung Cancer
NCT07920549Phase 3Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Sep 2036
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) (2 arms). Primary endpoint: Progression-Free Survival up to 60 months. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07920549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920549.